Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

"Quad Pill" Continues to Do Well in Early Study

February 2011

A new competitor to the only full-regimen pill on the market (Atripla) may emerge within another year or two with the continued development of the "quad pill". This combo pill includes three HIV drugs (the new integrase inhibitor elvitegravir + tenofovir + emtricitabine) and one non-HIV booster drug called cobicistat.

Two 48-week studies included about 150 people who had never been on HIV treatment. The first study compared the quad pill to Atripla, while the second evaluated cobicistat as a booster and compared cobicistat + Reyataz + Truvada to ritonavir + Reyataz + Truvada. CD4 counts ranged 341-436, viral loads were around 45,000, and no one had resistance to NRTIs, NNRTIs or protease inhibitors. Average age was about 35, and 9 out of 10 participants were men.

Advertisement

In the quad vs. Atripla study, higher CD4 count increases occurred with the quad pill (240 vs. 162). Also, side effects occurred less often (about 10%) in those taking the quad pill, and included nausea, vomiting and rash. In the cobicistat vs. ritonavir study, higher CD4 count increases occurred with cobicistat (230 vs. 206). Side effects also occurred less often with the cobicistat regimen, although more severe ones occurred with that regimen. Similar decreases in viral load to below 50 copies were seen in all four groups.

It appears that the new quad pill able to suppress HIV to undetectable levels equally as Atripla, perhaps without the side effects that many experience on Atripla due to Sustiva. It also appears that cobicistat is equal to ritonavir in boosting the protease inhibitor Reyataz.

However, an ongoing concern with cobicistat is its effect on kidney function. At 24 weeks, the drug caused a higher rate of abnormal kidney function in the quad pill study. Over the next 24 weeks, that change in function appeared to level off. Phase 3 study will help to distinguish this concern further.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. Visit Project Inform's website to find out more about their activities, publications and services.
 
See Also
More Research on Stribild (Elvitegravir/Cobicistat/FTC/Tenofovir)

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement